SOM Biotech and The Vall d’Hebron Institute of Research (VHIR) have signed an agreement to jointly develop the clinical Phase II of SOM0226 drug for transthyretin Amyloidosis (ATTR).
SOM Biotech and The Vall d’Hebron Institute of Research (VHIR) have signed an agreement to jointly develop the clinical Phase II of SOM0226 drug for transthyretin Amyloidosis (ATTR).